Long-Acting Injectable Antipsychotic Use in Patients with Schizophrenia and Criminal Justice System Encounters
**Background:** Nonadherence to medication is prevalent in persons diagnosed with schizophrenia, thus increasing the likelihood of relapse, poor health outcomes, hospitalization, high treatment costs, and high rates of both violent and non-violent offenses. **Objective:** To assess the association...
Saved in:
| Main Authors: | Madhav P. Bhatta, Saroj Bista, Antoine C. El Khoury, Eric G. Hutzell, Neeta Tandon, Douglas Smith |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Columbia Data Analytics, LLC
2021-05-01
|
| Series: | Journal of Health Economics and Outcomes Research |
| Online Access: | https://doi.org/10.36469/jheor.2021.22979 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Second-generation long-acting injectable antipsychotics in schizophrenia: patient functioning and quality of life
by: Montemagni C, et al.
Published: (2016-04-01) -
Subjective well-being in early-phase schizophrenia patients using long-acting injectable vs. oral antipsychotic drugs: data from the European Long-acting Antipsychotics in Schizophrenia Trial (EULAST)
by: Anna-Theresa Schulze, et al. -
Procyclidine Use with Long-Acting Injectable Antipsychotics
by: Prabin Gautam, et al.
Published: (2025-06-01) -
Procyclidine Use in Long-Acting Injectable Antipsychotics
by: Shalina Mitchell, et al.
Published: (2025-06-01) -
Aripiprazole Lauroxil: Development and Evidence-Based Review of a Long-Acting Injectable Atypical Antipsychotic for the Treatment of Schizophrenia
by: Citrome L, et al.
Published: (2025-03-01)